Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors
- Science. 2023 Nov 10;382(6671):eabo7201. doi: 10.1126/science.abo7201.
- 1. Pharmacology Graduate Program, Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA.
- 2. Program in Chemical Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- 3. Program in Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- 4. Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot, UK.
- 5. Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot, UK.
- 6. Oxford Biomedical Research Centre, National Institute for Health Research, University of Oxford, Oxford, UK.
- 7. Department of Chemical and Structural Biology, The Weizmann Institute of Science, Rehovot, Israel.
- 8. Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- 9. Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- 10. PostEra Inc., Cambridge, MA 02142, USA.
- 11. Department of Biochemistry, University of Johannesburg, Auckland Park, Johannesburg 2006, South Africa.
- 12. Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
- 13. Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.
- 14. Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
- 15. University of Oxford, Department of Biochemistry, Oxford Glycobiology Institute, South Parks Road, Oxford OX1 3QU, UK.
- 16. Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Computational and Systems Biology Program, New York, NY 10065, USA.
- 17. The Weizmann Institute of Science, Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Rehovot, 7610001, Israel.
- 18. University of Oxford, Nuffield Department of Medicine, Centre for Medicines Discovery, Oxford, OX3 7DQ, UK.
- 19. University of Oxford, Nuffield Department of Medicine, Target Discovery Institute, Oxford, OX3 7FZ, UK.
- 20. Enamine Ltd, Kyiv, 02094, Ukraine.
- 21. Taras Shevchenko National University of Kyiv, Kyiv, 01601, Ukraine.
- 22. Folding@Home Consortium.
- 23. Drugs for Neglected Diseases Initiative (DNDi), Geneva, 1202, Switzerland.
- 24. University of Pennsylvania, Departments of Biochemistry and Biophysics and Bioengineering, Philadelphia, PA 19083, USA.
- 25. University of Oxford, Department of Chemistry, Chemistry Research Laboratory, Oxford, OX1 3TA, UK.
- 26. Sai Life Sciences Limited, ICICI Knowledge Park, Shameerpet, Hyderabad 500 078, Telangana, India.
- 27. UCB, Slough, SL1 3WE, UK.
- 28. University of Oxford, Department of Statistics, Oxford OX1 3LB, UK.
- 29. Takeda Development Center Americas, Inc., San Diego, CA 92121, USA.
- 30. Argonne National Lab, Lemont, IL 60439, USA.
- 31. Cauldron Development Oy, Helsinki, 00140, Finland.
- 32. Cambridge Crystallographic Data Centre, Cambridge, CB2 1EZ, UK.
- 33. University of Milan, Department of General and Organic Chemistry, Milan, 20133, Italy.
- 34. Life Compass Consulting Ltd, Macclesfield, SK10 5UE, UK.
- 35. The University of Cambridge, Cambridge Institute for Medical Research, Department of Haematology, Cambridge CB2 0XY, UK.
- 36. Present address: Altos Labs, BioML group, Great Abington, CB21 6GP.
- 37. PostEra Inc., Cambridge, MA, 02142, USA.
- 38. KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
- 39. Datryllic LLC, Phoenix AZ, 85003, USA.
- 40. Informatics Matters Ltd, Bicester, OX26 6JU, UK.
- 41. Stanford University, Department of Chemistry, Stanford, CA 94305, USA.
- 42. Northeastern University, Department of Chemistry and Chemical Biology, Boston MA 02115, USA.
- 43. Thames Pharma Partners LLC, Mystic, CT 06355, USA.
- 44. University of Sao Paulo, Sao Carlos Institute of Physics, Sao Carlos, 13563-120, Brazil.
- 45. University of Leeds, School of Chemistry, Leeds, LS2 9JT, UK.
- 46. Present address: Exscientia, Oxford Science Park, Oxford, OX4 4GE, UK.
- 47. The Weizmann Institute of Science, Department of Chemical and Structural Biology, Rehovot, 7610001, Israel.
- 48. Icahn School of Medicine at Mount Sinai, Department of Microbiology, New York, NY 10029, USA.
- 49. Icahn School of Medicine at Mount Sinai, Global Health and Emerging Pathogens Institute, New York, NY 10029, USA.
- 50. Icahn School of Medicine at Mount Sinai, Department of Medicine, Division of Infectious Diseases, New York, NY 10029, USA.
- 51. Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY 10029, USA.
- 52. Icahn School of Medicine at Mount Sinai, Department of Pathology, Molecular and Cell-Based Medicine, New York, NY 10029, USA.
- 53. Present address: University of Groningen, Groningen Research Institute of Pharmacy, Department of Drug Design, Groningen, 9700 AV, Netherlands.
- 54. Present address: Merck Healthcare KGaA, Darmstadt, 64293, Germany.
- 55. University of Cambridge, Department of Chemistry, Cambridge, CB2 1EW, UK.
- 56. MedChemica Ltd, Macclesfield, Cheshire. SK11 6PU UK.
- 57. Illinois Institute of Technology, Department of Biology, Chicago IL 60616 USA.
- 58. University of Sussex, Department of Chemistry, School of Life Sciences, Brighton, East Sussex, BN1 9QJ, UK.
- 59. Syngene International Limited, Headington, Oxford, OX3 7BZ, UK.
- 60. Present address: Sir William Dunn School of Pathology, Oxford. OX1 3RE, UK.
- 61. University of Massachusetts, Chan Medical School, Department of Biochemistry and Molecular Biotechnology, Worcester MA 01655, USA.
- 62. Temple University, Department of Chemistry, Philadelphia, PA 19122, USA.
- 63. RWTH Aachen University, Institute of Experimental Medicine and Systems Biology, Aachen, 52074, Germany.
- 64. UCB, Chemin du Foriest, 1420 Braine-l'Alleud, Belgium.
- 65. Present address: AMSilk, Neuried, 82061, Germany.
- 66. Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Tri-Institutional Program in Computational Biology and Medicine, New York, NY 10065, USA.
- 67. Illinois Institute of Technology, Department of Applied Mathematics, Chicago IL 60616 USA.
- 68. University of Thessaly, Department of Biochemistry and Biotechnology, Larissa, 415 00, Greece.
- 69. Berwick-on-Sea, North Coast Road, Blanchisseuse, Saint George, Trinidad and Tobago.
- 70. Present address: University College of London, Department of Chemistry, London WC1H 0AJ, UK.
- 71. M2M solutions s.r.o. Žilina, 010 01, Slovakia.
- 72. MAX IV Laboratory, Fotongatan 2, 224 84 Lund, Sweden.
- 73. Present address: Charm Therapeutics, London, N1C 4AG, UK.
- 74. University of Cambridge, Cavendish Laboratory, Cambridge, CB3 0HE UK.
- 75. Radboud University Medical Center, Department of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Nijmegen, 6525 GA, Netherlands.
- 76. University of Aberdeen, Department of Chemistry, Old Aberdeen, AB24 3UE Scotland, UK.
- 77. University of Coimbra, CFisUC, Department of Physics, Coimbra, 3004-516, Portugal.
- 78. Illinois Institute of Technology, Department of Chemistry, Chicago IL 60616 USA.
- 79. University of Nebraska Medical Centre, Dept of Pathology and Microbiology, Omaha, NE 68198-5900, USA.
- 80. Relay Therapeutics, Cambridge, MA 02139, USA.
- 81. Present address: Instituto Butantan, Sao Paulo, 05503-900, Brazil.
- 82. Present address: Monte Rosa Therapeutics, Basel, CH 4057, Switzerland.
- 83. Present address: Medicxi, Geneva, 1204, Switzerland.
- 84. Present address: Sun Pharma Advanced Research Company (SPARC), Baroda, India.
- 85. University of São Paulo, Ribeirão Preto School of Pharmaceutical Sciences, Ribeirão Preto - SP/CEP 14040-903, Brazil.
- 86. Present address: Evotec (UK) Ltd, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UK.
- 87. Compass Bussiness Partners Ltd, Southcliffe, Bucks, SL9 0PD, UK.
- 88. Charité - Universitätsmedizin Berlin, In silico Toxicology and Structural Bioinformatics, Berlin, 10117, Germany.
- 89. Present address: Eli Lilly and Company, San Diego, CA 92121, USA.
- 90. Radboud University Medical Center, Department of pathology, Radboud Institute for Molecular Life Sciences, Nijmegen, 6525 GA, Netherlands.
- 91. Present address: TCG Life Sciences, Pune, India.
- 92. University of Oxford, Nuffield Department of Medicine, Wellcome Centre for Human Genetics, Oxford OX3 7BN, UK.
- 93. Lhasa Limited, Leeds, LS11 5PS, UK.
- 94. Present address: Walter and Eliza Hall Institute, Parkville 3052, Victoria, Australia.
- 95. Collaborative Drug Discovery, Cambridge, CB2 1GE, UK.
- 96. Present address: Lonza Biologics, Lonza Ltd, Lonzastrasse, CH-3930 Visp, Switzerland.
- 97. Present address: uniQure Biopharma, Amsterdam, 1105 BP, Netherlands.
- 98. Present address: Saarland University, Data Driven Drug Design, Campus - E2.1, 66123 Saarbrücken, Germany.
- 99. Walter Ward Consultancy and Training, Derbyshire, SK22 4AA, UK.
- 100. Collaborative Drug Discovery, Burlingame, CA 94010, USA.
- 101. University of Oxford, Nuffield Department of Medicine, Pandemic Sciences Institute, Oxford, Oxon, OX3 7DQ, UK.
- # Contributed equally.
We report the results of the COVID Moonshot, a fully open-science, crowdsourced, and structure-enabled drug discovery campaign targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease. We discovered a noncovalent, nonpeptidic inhibitor scaffold with lead-like properties that is differentiated from current main Protease Inhibitors. Our approach leveraged crowdsourcing, machine learning, exascale molecular simulations, and high-throughput structural biology and chemistry. We generated a detailed map of the structural plasticity of the SARS-CoV-2 main protease, extensive structure-activity relationships for multiple chemotypes, and a wealth of biochemical activity data. All compound designs (>18,000 designs), crystallographic data (>490 ligand-bound x-ray structures), assay data (>10,000 measurements), and synthesized molecules (>2400 compounds) for this campaign were shared rapidly and openly, creating a rich, open, and intellectual property-free knowledge base for future anticoronavirus drug discovery.
-
Cat. No.Product NameDescriptionTargetResearch Area
-